Bioptamers

Personalized precision therapies

Bioptamers operates in human health based in United States, founded in 2019.

Profile

At Bioptamers, we spot the molecular differences between tumor cells and healthy cells and create personalized molecules to deliver chemo- and radio- immunotherapies. Our platform develops molecules that selectively bind to the patient’s cancer cells, allowing personalized precision therapies.

Bioptamers is positioned in human health, a segment that rewards a clear, focused offering.

United States is where the company is located.

The company is listed at the SOSV portfolio company stage of development.

The company reports a headcount in the 2-10 range.

Total disclosed funding stands at about $168K.

Website: bioptamers.com